Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -561.22% | -422.13% | -1,640.40% | 221.17% | -24.94% |
| Total Depreciation and Amortization | 46.98% | 25.61% | 39.00% | 45.84% | 342.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -336.54% | -21.64% | 682.32% | 53.56% | -327.74% |
| Change in Net Operating Assets | 150.69% | 267.53% | -155.02% | -43.19% | 15.11% |
| Cash from Operations | -123.82% | 2,565.12% | -103.95% | 170.92% | -36.06% |
| Capital Expenditure | 21.79% | -45.90% | -321.54% | 3.61% | 76.99% |
| Sale of Property, Plant, and Equipment | -61.11% | 500.00% | -92.03% | 100.00% | -91.74% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 499.16% | -238.07% | 189.76% | 65.72% | 123.75% |
| Cash from Investing | 620.61% | -255.31% | 192.22% | 47.76% | 116.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.17% | -98.57% | -76.11% | -86.63% | 8,638.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.51% | -- | 100.00% | 730.00% | -3,082.35% |
| Cash from Financing | -100.04% | -98.44% | -67.01% | 12.65% | 12,877.56% |
| Foreign Exchange rate Adjustments | 1,707.50% | 470.00% | 149.80% | 10.38% | 48.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.98% | -86.66% | 17.79% | 1,793.07% | 202.90% |